Fed. Circ. Guidance For Pharma Method-Of-Use Patent Cases
On Nov. 9, 2017, the Federal Circuit confirmed that the overall content of a generic drug manufacturer's labeling, as well as real-world evidence of physician practices, inform the induced infringement analysis...To view the full article, register now.
Already a subscriber? Click here to view full article